YiChang HEC ChangJiang Pharmaceutical Announces Shareholders’ Meeting for Merger Approval
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H ( ($HK:1558) ) has shared an announcement. YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H ( ($HK:1558) ) has shared an announcement. YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
The Pharmaceutical Society of Sri Lanka (PSSL) announced its flagship event, the 43rd Annual General Meeting and the Scientific Sessions 2025, and the award ceremony which will be held on June 29, 2025 at Waters Edge,
A high-level overview of Teva Pharmaceutical Industries Limited (TEVA) stock. View (TEVA) real-time stock price, chart, news, analysis, analyst reviews and more.
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and …
Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its wholly-owned subsidiary T-mab has entered into an agreement with Qilu Pharmaceutical for Albipagrastim alfa for Injection (R&D code: 8MW0511).
It doesn’t matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
Navamedic announces that the Swedish Medical Products Agency, acting as the Reference Member State, together with the Concerned Member States in 9 additional countries have approved OraFID® for use with a medicinal product.
Sun Pharmaceutical Industries Ltd. closed 13.89% below its 52-week high of 1,960.20 rupees, which the company achieved on September 30th.
Pharmaceutical drug delivery methods encompass a wide range of innovative solutions designed to enhance the efficacy, safety, and patient compliance of medications. In 2025, the global pharmaceutical drug delivery market is estimated to be valued at approximately USD 2,
BioMarin Pharmaceutical currently trades at $55.42, down from $62.77 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free). The Best Stocks for High-Quality Investors Donald …